Table 5.
Toxicity profile of 45 patients who underwent treatment with paclitaxel, ifosfamide, and nedaplatin as second‐line chemotherapy for metastatic urothelial carcinoma
| Toxicity | Grade (all cycles), no. of patients (%) | |||
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |
| Hematologic | ||||
| Leukopenia | 0 (0) | 2 (4.4) | 21 (46.7) | 21 (46.7) |
| Neutropenia | 0 (0) | 1 (2.2) | 2 (4.4) | 41 (91.1) |
| Thrombocytopenia | 10 (22.2) | 10 (22.2) | 5 (11.1) | 3 (6.7) |
| Anemia | 10 (22.2) | 14 (31.1) | 7 (15.6) | 0 (0.0) |
| Febrile neutropenia | 10 (22.2) | |||
| Non‐hematologic | ||||
| Anorexia | 12 (26.7) | 13 (28.9) | 2 (4.4) | 0 (0.0) |
| Vomiting | 3 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Peripheral neuropathy | 0 (0.0) | 7 (15.6) | 0 (0.0) | 0 (0.0) |
| AST/ALT, elevated | 0 (0.0) | 0 (0.0) | 1 (2.2) | 0 (0.0) |
| Creatinine, elevated | 0 (0.0) | 1 (2.2) | 0 (0.0) | 0 (0.0) |
| Alopecia | 0 (0.0) | 45 (100.0) | 0 (0.0) | 0 (0.0) |
Toxic effects were graded in agreement with National Cancer Institute Common Toxicity Criteria, version 3.0. ALT, alanine transaminase; AST, aspartate transaminase.